Evolocumab  (Synonyms: 依洛尤单抗; AMG 145)

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation^[1][2][3].

PCSK9^[1]

Evolocumab (5-100 μg/mL) 可显著阻止 H₂O₂ 对人脐静脉内皮细胞 (HUVEC) 的细胞毒性^[2]。
Evolocumab (100 μg/mL) 可减少大鼠视网膜 Müller 细胞 (RMC) 受刺激而增加的炎症因子的表达和分泌^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1256937-27-5

液体

Colorless to light yellow

依洛尤单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fala L, et, al. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.  [Content Brief]

  [2]. Zhou Q, et al. Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions. J Diabetes Complications. 2023 Oct;37(10):108593.  [Content Brief]

  [3]. Safaeian L, et al. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress. Arch Physiol Biochem. 2022 Dec;128(6):1681-1686.  [Content Brief]